InvestorsHub Logo

Timothy Smith

09/28/15 10:18 PM

#39 RE: OTCdoc #37

On the recent news. Stifel downgrades EMES to Sell with an $8 price target and sharply reduces earnings estimates, noting this is the third time management has revised 2015 guidance.

Also pointing out looming debt covenant issues, Baird cuts EMES to Underperform with a $7 target and expects weakness in other proppant producers, including CRR, FMSA, HCLP and SLCA (Briefing.com).